Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04610528
Title A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3)
Acronym TOT-HER3
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.